Therefore, inclusion of a checkpoint inhibitor (e.g. anti-PD-L1, anti-CTLA4) or CY in the regimen substantially improved the therapeutic effectiveness that completely eradicated transplanted HCC (Figures 1, 3, & 5). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.